C

Cadrenal Therapeutics Inc
NASDAQ:CVKD

Watchlist Manager
Cadrenal Therapeutics Inc
NASDAQ:CVKD
Watchlist
Price: 7.94 USD -3.76%
Market Cap: 16.5m USD

Intrinsic Value

The intrinsic value of one CVKD stock under the Base Case scenario is 4.82 USD. Compared to the current market price of 7.94 USD, Cadrenal Therapeutics Inc is Overvalued by 39%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CVKD Intrinsic Value
4.82 USD
Overvaluation 39%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation History
Cadrenal Therapeutics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about CVKD?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is CVKD valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Cadrenal Therapeutics Inc.

Explain Valuation
Compare CVKD to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CVKD?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Cadrenal Therapeutics Inc

Balance Sheet Decomposition
Cadrenal Therapeutics Inc

Current Assets 4.1m
Cash & Short-Term Investments 3.9m
Receivables 12.8k
Other Current Assets 206.8k
Non-Current Assets 7.9k
PP&E 5.7k
Other Non-Current Assets 2.2k
Current Liabilities 1.4m
Accounts Payable 614.1k
Accrued Liabilities 702.9k
Other Current Liabilities 35.7k
Efficiency

Free Cash Flow Analysis
Cadrenal Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Cadrenal Therapeutics Inc

Revenue
0 USD
Operating Expenses
-14.7m USD
Operating Income
-14.7m USD
Other Expenses
288.8k USD
Net Income
-14.4m USD
Fundamental Scores

CVKD Profitability Score
Profitability Due Diligence

Cadrenal Therapeutics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional ROIC
Low 3Y Average Gross Margin
Low 3Y Average Net Margin
Low 3Y Average Operating Margin
36/100
Profitability
Score

Cadrenal Therapeutics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

CVKD Solvency Score
Solvency Due Diligence

Cadrenal Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
56/100
Solvency
Score

Cadrenal Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CVKD Price Targets Summary
Cadrenal Therapeutics Inc

Wall Street analysts forecast CVKD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CVKD is 36.38 USD with a low forecast of 30.3 USD and a high forecast of 47.25 USD.

Lowest
Price Target
30.3 USD
282% Upside
Average
Price Target
36.38 USD
358% Upside
Highest
Price Target
47.25 USD
495% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Cadrenal Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CVKD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

CVKD Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one CVKD stock?

The intrinsic value of one CVKD stock under the Base Case scenario is 4.82 USD.

Is CVKD stock undervalued or overvalued?

Compared to the current market price of 7.94 USD, Cadrenal Therapeutics Inc is Overvalued by 39%.

Back to Top